Lipoproteins and CETP levels as risk factors for severe sepsis in hospitalized patients

Abstract

BackgroundThe magnitude of lipoprotein level reduction during the acute-phase response may be associated with the severity and mortality of sepsis. However, it remains to be determined whether low lipoprotein levels can be considered a risk factor for developing sepsis. We aimed to investigate lipoprotein levels as risk factors for sepsis in hospitalized patients, and also describe sequential changes in lipoprotein and cholesterol ester transfer protein (CETP) levels during sepsis.

Monocyte chemoattractant protein-1 and paraoxonase-1 and 3 levels in patients with sepsis treated in an intensive care unit: a preliminary report

“…However, during the acute phase response, apolipoprotein A1, PON1 and PON3 in the HDL particle are replaced by acute phase proteins, these changes transform the acute phase HDL in a pro-infl ammatory particle, unable to protect LDL from oxidation and to inhibit migration of macrophages, which leads further infl ammation (33 -36) . A previous study supports the idea that low basal serum HDL cholesterol may be considered a risk factor for the development of severe sepsis in hospitalised patients (37) .…”

Elevated CETP activity during acute phase of myocardial infarction is independently associated with endothelial dysfunction and adverse clinical outcome

“…In severe sepsis, in-hospital mortality was reported to be inversely related to CETP activity [3]. In transgenic animal models of sepsis, CETP mediates the transfer of circulating endotoxins to HDL, increasing their hepatic uptake and attenuating the systemic inflammatory response [1].…”

Cholesteryl ester transfer protein: The controversial relation to atherosclerosis and emerging new biological roles

“…In summary, the sepsis related deaths in torcetrapib-treated patients (16), hospitalized patients with reduced CETP (63), and LPS-injected CETP deficient mice (59) comprise a strong set of evidence for the protective action of CETP on acute inflammation that cannot be ignored any longer and must be taken into account in future studies of CETP inhibition.…”